PMID- 35587661
OWN - NLM
STAT- MEDLINE
DCOM- 20220523
LR  - 20220531
IS  - 1006-7248 (Print)
IS  - 1006-7248 (Linking)
VI  - 31
IP  - 1
DP  - 2022 Feb
TI  - [Mechanism of microRNA-100-5p on mammalian target of rapamycin in 
      temporomandibular arthritis].
PG  - 12-16
AB  - PURPOSE: To investigate the mechanism of microRNA-100-5p (miR-100-5p) on 
      mammalian target (mTOR) of rapamycin in temporomandibular arthritis. METHODS: 
      Sixty SD rats were randomly divided into group A, group B, group C, group D, and 
      group E, with 12 rats in each group. Rat models of temporomandibular arthritis 
      were prepared by injecting sodium iodoacetate solution into the bilateral spaces 
      of temporomandibular joint. After establishment, group C was injected 
      pcDNA3.1-miR-100-5p recombinant plasmid, group D was injected mTOR inhibitor 
      rapamycin, group E was injected with pcDNA3.1-miR-100-5p recombinant plasmid and 
      rapamycin, and group A was injected same amount of normal saline in the same way. 
      Various indexes were observed in each group, including morphological changes of 
      temporomandibular joint tissues, matrix metalloproteinase-3 (MMP-3), MMP-1, 
      MMP-13, interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), interleukin 6 
      (IL-6), miR-100-5p, mTOR expression. The data were processed using SPSS 22.0 
      software package. RESULTS: In group B, the structure of temporomandibular joint 
      was fuzzy, with synovial hyperplasia, vascular dilatation, clustered cells and a 
      large amount of inflammatory infiltration. Histopathological changes of 
      temporomandibular joint in each interventional group were improved to different 
      degrees compared with group B, among which group E showed the most obvious 
      improvement. The levels of MMP-3, MMP-1, MMP-13, IL-6, IL-1beta and TNF-alpha in group B 
      were significantly higher than those in group A(P＜0.05). The levels of MMP-3, 
      MMP-1, MMP-13, IL-6, IL-1beta and TNF-alpha in group C, group D and group E were 
      significantly lower than those in group B(P＜0.05). The levels of MMP-3, MMP-1, 
      MMP-13, IL-6, IL-1beta and TNF-alpha in group D were not significantly different from 
      those in group C (P＜0.05). The levels of MMP-3, MMP-1, MMP-13, IL-6, IL-1beta and 
      TNF-alpha in group E were significantly lower than those in group D (P＜0.05). The 
      expression level of miR-100-5p in group E was significantly higher than that in 
      group B (P＜0.05). The expression level of mTOR protein in group E was 
      significantly lower than that in group B (P＜0.05). CONCLUSIONS: MicroRNA-100-5p 
      may alleviate temporomandibular arthritis by down-regulating the expression of 
      mTOR.
FAU - Wan, Zhi-Qun
AU  - Wan ZQ
AD  - Department of Stomatology, Ji'an Central People's Hospital of Jiangxi Province. 
      Ji'an 343000, China. E-mail: ech898@126.com.
FAU - Zhou, Zheng-Gen
AU  - Zhou ZG
FAU - Wang, Jing
AU  - Wang J
FAU - Zhou, Qun
AU  - Zhou Q
LA  - chi
PT  - Journal Article
PL  - China
TA  - Shanghai Kou Qiang Yi Xue
JT  - Shanghai kou qiang yi xue = Shanghai journal of stomatology
JID - 101090220
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 0 (MicroRNAs)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.4.24.- (Matrix Metalloproteinase 13)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - EC 3.4.24.7 (Matrix Metalloproteinase 1)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - *Arthritis
MH  - Interleukin-1beta/genetics/metabolism
MH  - Interleukin-6
MH  - Mammals/metabolism
MH  - Matrix Metalloproteinase 1
MH  - Matrix Metalloproteinase 13
MH  - Matrix Metalloproteinase 3
MH  - *MicroRNAs/genetics/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sirolimus
MH  - TOR Serine-Threonine Kinases/genetics
MH  - *Temporomandibular Joint Disorders/chemically induced/genetics
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2022/05/20 06:00
MHDA- 2022/05/24 06:00
CRDT- 2022/05/19 15:38
PHST- 2022/05/19 15:38 [entrez]
PHST- 2022/05/20 06:00 [pubmed]
PHST- 2022/05/24 06:00 [medline]
PST - ppublish
SO  - Shanghai Kou Qiang Yi Xue. 2022 Feb;31(1):12-16.